Compare HLX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLX | NVCR |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1996 | 2015 |
| Metric | HLX | NVCR |
|---|---|---|
| Price | $9.05 | $12.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $10.50 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $876,561,000.00 | $655,353,000.00 |
| Revenue This Year | $2.91 | $7.72 |
| Revenue Next Year | $4.97 | $6.74 |
| P/E Ratio | $43.60 | ★ N/A |
| Revenue Growth | 3.60 | ★ 8.28 |
| 52 Week Low | $5.52 | $9.82 |
| 52 Week High | $10.75 | $20.05 |
| Indicator | HLX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.63 | 60.84 |
| Support Level | $6.20 | $12.66 |
| Resistance Level | $9.90 | $13.34 |
| Average True Range (ATR) | 0.32 | 0.54 |
| MACD | -0.10 | 0.29 |
| Stochastic Oscillator | 9.50 | 84.84 |
Helix Energy Solutions Group Inc is an offshore energy services company. It provides specialty services to the offshore energy industry, with an emphasis on well intervention and robotics operations. Helix provides services in deep water in the Gulf of Mexico, Brazil, the North Sea, Asia Pacific and West Africa regions. It has four segments: Well Intervention, Robotics, Shallow Water Abandonment and Production Facilities. The Well Intervention segment includes vessels and equipment used to perform well intervention services in the Gulf of Mexico, the North Sea and Brazil. It derives the majority of its revenue from the U.S., and it also has its presence in North Sea, Brazil, Asia Pacific, West Africa, and Other.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.